Stevens Capital Management LP lessened its position in shares of Agilent Technologies Inc (NYSE:A) by 74.7% in the second quarter, HoldingsChannel.com reports. The fund owned 48,218 shares of the medical research company’s stock after selling 142,116 shares during the period. Stevens Capital Management LP’s holdings in Agilent Technologies were worth $3,600,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. NEXT Financial Group Inc lifted its stake in Agilent Technologies by 22.0% in the 2nd quarter. NEXT Financial Group Inc now owns 925 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 167 shares during the last quarter. Greenwood Capital Associates LLC lifted its stake in Agilent Technologies by 4.1% in the 1st quarter. Greenwood Capital Associates LLC now owns 4,670 shares of the medical research company’s stock valued at $375,000 after purchasing an additional 185 shares during the last quarter. Fulton Bank N.A. lifted its stake in Agilent Technologies by 3.8% in the 2nd quarter. Fulton Bank N.A. now owns 5,235 shares of the medical research company’s stock valued at $391,000 after purchasing an additional 194 shares during the last quarter. Destination Wealth Management lifted its stake in Agilent Technologies by 100.0% in the 1st quarter. Destination Wealth Management now owns 400 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 200 shares during the last quarter. Finally, Flagship Harbor Advisors LLC lifted its stake in Agilent Technologies by 139.0% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 349 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 203 shares during the last quarter.

Shares of A traded up $5.19 during trading hours on Thursday, reaching $70.78. 1,951,566 shares of the stock traded hands, compared to its average volume of 2,663,109. The company has a current ratio of 3.41, a quick ratio of 2.82 and a debt-to-equity ratio of 0.35. The stock has a fifty day moving average price of $70.86. Agilent Technologies Inc has a 52 week low of $61.01 and a 52 week high of $82.27. The stock has a market cap of $21.05 billion, a P/E ratio of 25.37, a price-to-earnings-growth ratio of 1.86 and a beta of 1.41.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 14th. The medical research company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. Agilent Technologies had a net margin of 22.25% and a return on equity of 19.71%. The company had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period last year, the firm earned $0.67 earnings per share. The firm’s revenue was up 5.6% on a year-over-year basis. As a group, sell-side analysts expect that Agilent Technologies Inc will post 3.05 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd were given a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.93%. The ex-dividend date of this dividend was Monday, July 1st. Agilent Technologies’s payout ratio is currently 23.66%.

Several research firms have recently issued reports on A. Piper Jaffray Companies raised their price target on shares of Agilent Technologies from $83.00 to $86.00 and gave the company an “overweight” rating in a research note on Thursday. ValuEngine downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Friday, July 12th. Wolfe Research assumed coverage on shares of Agilent Technologies in a research report on Thursday, May 30th. They set a “peer perform” rating for the company. Deutsche Bank decreased their price objective on shares of Agilent Technologies from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, May 15th. Finally, Zacks Investment Research cut shares of Agilent Technologies from a “hold” rating to a “sell” rating and set a $71.00 price objective for the company. in a research report on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and ten have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $84.15.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Story: Analyzing a company’s cash flow statement

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.